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Abstract A commentary is presented on the urgent need
for a comprehensive effort to improve the practice of
pediatric therapeutics in Africa. A call for action is
addressed to a variety of practitioners internationally, many
of whom possess skills that could be fruitfully applied to
the improvement of health outcomes for African children.
Successful engagement with the many challenges requires
the complementary effort of researchers in basic and clin-
ical pharmacology and toxicology, nurses, pharmacists,
physicians, clinical pharmacologists, clinical pharmacists,
and political leaders and civil servants. While a compre-
hensive or systematic review of the relevant literature has
not been attempted, the authors have highlighted promising
initiatives driven by international agencies and academic
networks. Two African perspectives are presented to rein-
force the prospect of child health gains that can be
achieved through consistent pursuit of optimal therapy for
conditions such as respiratory infection, diarrhea, malaria,
and HIV/AIDS. There is an imperative for development of
north–south and south–south partnerships that will amplify
current research efforts and mobilize existing knowledge
concerning pediatric drugs. The overall goal is a multi-
disciplinary commitment to making essential medicines
available at the right time, the right place, and in the right
formulation for African children from infancy to
adolescence.
1 Introduction
The challenge of delivering optimal drug therapy to chil-
dren in Africa is undeniably complex and compounded by
a shortage of both human and fiscal resources [1, 2]. While
much has been written about the worldwide failure of
commitment over the past century to achieve evidence-
based pediatric therapy [3, 4], in the 54 countries of Africa
the situation is even more critical. African nations, along
with some Asian counterparts, are subject to a dispropor-
tionate burden of childhood illnesses with related morbid-
ity and mortality [5]. The African challenge is shown
symbolically in Fig. 1, which presents a sample of six
maps from those available on Worldmapper.org showing
the maldistribution of illness burden and fiscal resources to
support treatment [6].
In the past 20 years, international funders and agencies
such as WHO, UNICEF, Save the Children, the Wellcome
Trust, and the Clinton and Bill & Melinda Gates Founda-
tions, among others, have recognized the importance of
improved nutrition and optimal drug therapy as the most
cost-effective interventions capable of saving lives and
reducing morbidity among newborns, infants and young
children. An extremely important advance has been WHO’s
promulgation since 2005 of integrated management of
childhood illness (IMCI) [7], with the objective of cutting
across vertical disease-based approaches. Nonetheless,
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optimal treatment remains elusive in many parts of Africa
for conditions such as neonatal sepsis, childhood respiratory
infections, diarrhea, malaria, acute and chronic pain, and
HIV/AIDS.
In 2007, the World Health Assembly (WHA) recognized
the urgency of closing the gap in evidence supporting
childhood prescribing and passed WHA resolution 60.20
calling for better medicines for children [8]. Since that time,
an essential medicines list for children has been introduced
and has gone through two revisions [9]. Another good start
has been made in improving standardized treatment guide-
lines (STGs) for resource-poor settings through release of
the Model Formulary for Children by the WHO [10]. Fur-
thermore, an up-to-date revision of the well-travelled
‘‘pocket book’’ for acute care of children in resource-poor
settings [11] is scheduled for release in 2013. Work that has
been conducted under WHO’s Better Medicines for
Children program, with sponsorship from the Bill &
Melinda Gates Foundation, includes an emphasis on the
need for new formulations appropriate for use in remote
areas which are at times subject to climate extremes [12, 13].
The paper that follows offers a perspective on the
environment that is impeding achievement of better drug
therapy for children in Africa. The report is not intended as
a comprehensive review of African pediatric pharmacology
research, but rather as an environmental scan that rein-
forces the need for international cross-disciplinary effort.
Both global and regional strategies for improvement are
discussed. The required mix of political leadership, altered
human behavior, research development, innovative pro-
fessional education in medicine, pharmacy and nursing,
and improved clinical practice in therapeutics and toxi-
cology will not be easily achieved without comprehensive
focused effort from many quarters.
Early neonatal Infant mortality
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African nations display disproportionately high rates of infant and neonatal mortality and are home to much of the world’s vitamin A 
deficiency. Iron deficiency anemia is relatively common. Access to affordable drugs or public health services is suboptimal.
Affordable drugs Public health 
Fig. 1 Maldistribution of illness burden and fiscal resources to support treatment [6]
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The target audience for these remarks is a broad cross-
section of clinicians, researchers, and health care decision
makers who possess skills critical to the future improve-
ment of therapeutic outcomes for African children.
2 How Far Have We Come?
The 2011 report, ‘‘Assessing Progress in Africa toward the
Millennium Development Goals’’ [14, 15], describes mixed
improvement in African nations across a variety of indicators.
As things stand today, it appears certain that there has been
insufficient headway to permit full achievement of the Mille-
nium Development Goals (MDGs) as envisaged by 2015, and
this was confirmed last year by the annual report of Countdown
to 2015 [16] and in the analysis by Liu and colleagues [17]. In
general, progress that has been made in African nations favors
higher income groups and urban populations. Poorer, less
educated, rural groups continue to be marginalized. Although
all MDGs are interconnected, target 4a, of reducing the mor-
tality rate among children under 5 years of age by two-thirds
between 1990 and 2015, remains particularly elusive. An
overall 28 % reduction has been achieved over a period of
20 years; however, the under-5 mortality rate remains high in
the majority of African countries [18], with at least 22 still
registering rates greater than 100 deaths per 100,000 live births
in 2011 [19]. Where success has been achieved, the report
suggests that the most influential positive influences are
leadership commitment, strong partnerships, and enhanced
service delivery programs. Ready access to essential medi-
cines, appropriately used, is a critical condition for success.
The report concludes that further progress must include greater
availability of antibiotics for acute respiratory infections, oral
rehydration salts for diarrhea, improved immunization, use of
treated bednets, and access to appropriate antimalarial drugs.
A refocusing, specifically on pneumonia and diarrhea, two of
the three leading killers of young children in Africa, was urged.
The African Report on Child Well Being published by the
African Child Policy Forum in 2011 explored the obligation
of African societies to invest more heavily in their children
[20]. It underscored the importance of the national budget as a
key government policy document and advocates increased
budgetary allocations to sectors that most impact children’s
lives. Policy decisions by government should be based on the
principles of distributive justice, equity, provision for the
needs of all, freedom from poverty and discrimination, social
inclusion, and the development of human capabilities.
3 Better Medicines for Children: Essential Elements
In order for African nations to improve survival and lessen
morbidity for children, it will be mandatory to promote
better drug therapy. It is anticipated that required
improvements will be pursued within the context of broad,
established initiatives, including child survival strategies
[21], the IMCI strategy [22], and the Millennium Devel-
opment Goals [19, 20]. As described by the African Child
Policy Forum, the foundational effort will be heightened
investment in child-centered implementation strategies that
incorporate strong governance, leadership, the correct
number and skill mix of human resources, and improved
data and information management systems [20].
To avoid confusion, it will also be important in many
situations to carefully define the age range encompassed by
terms such as ‘pediatric’ or ‘child’. While the concerns of
adolescents are undeniably important, for the purposes
of this commentary it may be argued that the priority focus
of African pharmacotherapy interest should be on new-
borns, infants, and prepubertal children.
4 Requirements for a Robust Pediatric Pharmaceutical
Policy Framework
4.1 Essential Medicines Lists for Children
Initially, a review of the current national Essential Medi-
cines List (EML) in African countries is required to
determine whether the needs of children (neonates
to puberty) have been considered. It is also necessary to
perform a detailed assessment of burden of disease at the
country or regional level, and to build on all readily
available tools as listed in Table 1. Using such information,
each country will be positioned to develop an EML for
children (EMLc) that meets its own needs. It must be
consistent with current evidence-based standard treatment
guidelines and optimal procurement procedures. Ideally,
each country’s EMLc should be revised every 2 years;
however, given the widespread shortage in African nations
of highly qualified personnel with child health expertise in
relevant disciplines, this goal is likely to prove challenging.
4.2 Standard Treatment Guidelines
All countries in Africa can build on more than 30 years of
adult experience with essential medicines and the devel-
opment of national treatment guidelines. STGs directly
applicable to children will, however, be required if the
leading causes of mortality are to be addressed in a region-
specific manner. STGs must be created or revised and
linked to an EMLc that is relevant, applicable to the local/
regional setting, and compatible with available fiscal
resources. Once this is achieved, the subsequent process is
iterative and aimed at maintaining the guidelines and
providing necessary communication and educational
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activities in order to promote adherence at every level of
health care service and within the supply chain [23].
4.3 Adequate Number and Mix of Human Resources
Health manpower shortages in most African countries are
the greatest single impediment to progress toward better
medicines for children. There is a distinct shortage of
physicians trained in clinical pharmacology and toxicol-
ogy, clinical, hospital, and community pharmacists, phar-
maceutical scientists, nurses, and relevant researchers with
a critical role to play in promoting safe and effective drug
therapy. Significant human resource limitations throughout
Africa impede the successful development of EMLc/STGs
and the knowledge transfer and mobilization activities
required to assure widespread engagement with active
interventions. Strategies to acquire dedicated fiscal
resources to increase training opportunities for health care
workers and community health volunteers across all rele-
vant disciplines must be identified and implemented.
Attention should also be paid to ensuring the appropriate
mix and distribution of personnel alongside improved
implementation of retention initiatives to minimize brain
drain [24–29].
A parallel opportunity exists for thorough exploration of
task-shifting innovations that have much to offer in Africa.
The North American/European idealized model of the sub-
specialist clinician scientist is unlikely to be adopted
quickly in Africa. Attention should be paid alternatively to
the training and technical support of dedicated teams
aligned with objectives of patient-centered care and
improved clinical outcomes that may be achieved through
extended application of strengthened STGs. Africa also
needs a new clinical research model and provides an
extraordinary opportunity for innovation that may achieve
some of the outcomes that still remain an elusive target in
more economically developed regions [30].
4.4 Data Availability
The best achievable baseline data for each African country,
disaggregated by locality and region, will ultimately be
required in order to identify the burden of illness for
common childhood conditions and guide development of
STGs. The enhanced use of modern wireless technology
should facilitate the collection of relevant health data with
significant impact on the ability to plan research studies
and to prioritize clinical interventions. At a minimum,
required data elements include those relevant to therapeutic
research and shown in Table 2 [23].
4.5 Relevant Clinical Research
There is an enormous need for further development of clinical
research capacity in Africa relevant to the needs of children.
More clinical trials should be conducted in African settings,
and work should continue as initiated by WHO on the devel-
opment of a framework for support and management of such
trials. The training of highly qualified personnel able to par-
ticipate in clinical pediatric trials in low- and middle-income
countries is a mandatory component of any such effort [31, 32].
StaR Child Health, an important resource group supporting
and advocating augmented clinical research capacity for chil-
dren, has emerged in the last 5 years: ‘‘a group of methodol-
ogists, clinicians and policy makers who seek to enhance the
quality, ethics and reliability of pediatric clinical research by
promoting use of evidence-based standards or guidance for
clinical studies with children.’’ Beginning with an initial
meeting in 2009, StaR Child Health has already focused on the
needs of clinical trialists in low- and middle-income settings
[31, 32], and this emphasis has been maintained through sub-
sequent meetings in 2010 and 2012 [33] and by the publication
of an initial set of six research standards in 2012 [34–39].
The key objectives described for StaR Child Health
include the following [33]:
• raising awareness of the crucial importance of research
design, conduct. and reporting of clinical research;
• assisting in the development, dissemination. and imple-
mentation of evidence-based standards for clinical
research for children;
• becoming a global center providing resources and
supporting training related to the design, conduct, and
reporting of clinical research in children;
• conducting empirical research on design, conduct, and
reporting of clinical research.
4.6 Knowledge Transfer
Knowledge transfer and mobilization activities are vital to
the establishment of any program promising better
Table 1 Tools available to guide design of optimal programmes for
pediatric drug therapy
• Millennium Development Goals
• WHO EMLc, 3rd edition
• WHO Model Formulary for Children
• WHO pocketbook of hospital care for children in resource poor
settings
• Framework for integrated management of childhood illness
(IMCI)
• Current textbooks of pediatric clinical pharmacology and
therapeuticsa
• Other national formularies for treatment of childrenb
EMLc Essential Medicines List for children
a For example, Yaffe and Aranda [90]
b For example, British National Formulary for Children [91]
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medicines for African children. These activities include the
creation and dissemination of up-to-date country-level
EMLcs, and the provision of accurate information to
patients and health workers at the point of care.
Individuals working in the fields of medicine, pharmacy,
nursing, and allied health programs need up-to-date infor-
mation regarding EMLcs and STGs at every level of
training, from undergraduate through to specialization and
continuing education. There is also a demand for education
regarding the special needs of children directed to indi-
viduals, such as those on therapeutic drug committees,
employed within the pharmaceutical industry and local
manufacturers, and policy makers and administrators at all
levels of the health care delivery system.
To achieve this goal, all educators must also have access
to the most current and accurate information and tools.
Novel and locally applicable knowledge translation and
dissemination activities must be identified and put in place,
in order to ensure that essential information reaches all the
aforementioned in a timely and efficient manner, regardless
of geographical, technological, and/or other barriers. Pro-
fessional organizations can be pivotal in recognizing the
importance of disseminating information pertaining to
pediatric care, and could help in a significant way to
advance these goals [40, 41].
4.7 Regulation, Procurement, Adherence, and Quality
Monitoring
In order to make the best and most rational procurement
decisions, a region-specific understanding of burden of
disease and historical purchase and utilization profile is
necessary. Purchasing processes can be supported by
national pricing policies and guidelines, as well as through
buying based on a tendering process and the purchasing of
medications in bulk [42]. Although generic formulations
are usually cheaper to acquire, the use of generics must be
tempered by careful investigation of quality. The WHO
prequalification process is seen as enhancing a rational
procurement process, and consideration might be given to
expanding its use [43]. The establishment of a global vir-
tual warehouse of quality, sources, and prices of medicines
for children would convey significant advantage in future.
Clearly, a significant opportunity exists for national
regulatory authorities in high-income countries to play a
critical supporting role if teamed with counterparts in
Africa. The potential advantages of such partnerships have
been under active discussion since 2008, with leadership
from the International Conference of Drug Regulatory
Authorities (ICDRA) and the network of regulatory
authorities for pediatric medicines [44].
There are precedents for success to be seen in the work
of the Pan American Health Organization in encouraging
stronger regulators in Brazil and Mexico to seek synergies
with other Latin American counterparts [45].
Technology is already providing innovative ways to
monitor the quality of drugs. One such example is the use
of a text-messaging verification system to address the
identification of counterfeit pharmaceuticals in Africa
which is now in use for a small number of drugs in selected
countries [46].
Efforts to engage children and their families in decision
making about treatment is vitally important to encourage-
ment of adherence with therapeutic regimens and
achievement of better outcomes. New approaches such as
regular cellphone communication may contribute greatly to
improved adherence, even in jurisdictions with low health
literacy [47].
5 Back to Reality
The literature is replete with descriptions of the challenges
faced by those who wish to improve therapeutic outcomes
for mothers, newborns, infants, and children. For illustra-
tion, two African perspectives are presented here. One
describes efforts to better manage the control and treatment
of diarrhea, pneumonia, and malaria. The second is a
success story from Botswana showing the remarkable
progress made in the prevention and treatment of childhood
HIV/AIDS. Both examples serve to demonstrate the
potential gains in child health from optimal clinical use of
drugs and vaccines.
Table 2 Data elements required as a foundation for African thera-
peutic choices
• Accurate demography and burden of illness measurements
• Data on current national expenditure for pediatric medicines
• Documentation of the availability of an essential pediatric drug
basket on the shelf at various levels within the health system
• Documentation of supply bottlenecks and occurrence of
stockouts
• Current prices of various formulations for children, including
liquids and dispersibles
• Regional costs for transportation and storage of liquid
preparations prepared at source
• Local and regional availability of pediatric dosage forms, supply
source and utilization monitoring
• Accurately described local use patterns for extemporaneous
preparations
• Aggregated, reliable data on adverse drug reactions, drug errors
and drug interactions
• Defined extent and frequency of antibiotic resistance (local and
regional)
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5.1 A Perspective on Major Infectious Causes
of Mortality
Diarrheal diseases, pneumonia, malaria, and HIV continue
to be responsible for most deaths among children under 5
years of age in sub-Saharan Africa, despite acceleration of
efforts for their containment through pursuit of relevant
Millennium Development Goals [14, 15]. Although out-
come statistics are changing rapidly with trends to
improved survival, there were still 7.6 million deaths
reported in 2010 [17] and 7.2 million deaths in 2011 among
children under 5 years of age [19]. The major causes of
mortality beyond the neonatal period in children under 5
years of age remain pneumonia (14.1 %), diarrhea (9.9 %),
and malaria (7.4 %), and this pattern appears to hold in
Africa as in other developing regions [19].
In absolute numbers, the greatest success in mortality
reduction in Africa has been seen in Ethiopia, Liberia,
Madagascar, Malawi, and Niger [48]. A common denom-
inator for good performance in these countries has been a
concerted public health approach that incorporates nutri-
tion, immunizations, breastfeeding, vitamin A supplemen-
tation, and safe water access. Nonetheless, uptake of low
cost interventions for pneumonia, diarrhea, and malaria,
which together are responsible for about one-third of
deaths in children under 5 years of age, has remained
unacceptably low [49].
Dramatic reductions in diarrhea have been achieved in
recent years. Simple measures such as hand-washing alone
have been shown to reduce diarrhea episodes by up to
30 % [50]. Although coverage with rotavirus vaccination
in low-income countries remains low, its effectiveness in
reducing the incidence and adverse impacts of the most
common cause of infective diarrhea has been established
[51]. Safer and more effective low osmolarity oral rehy-
dration solutions are also now available for use at home
and in health facilities [52].
A recent double-blind, randomized, placebo-controlled
trial has confirmed the utility of zinc as an adjunct treatment
of young infants with probable severe bacterial infections
[53]. Zinc supplementation could have additional benefits in
reducing duration and severity of diarrhea [54, 55]. Although
there is no evidence to suggest that addition of vitamin A and
zinc to acute pneumonia treatment improves outcome, [56,
57] zinc supplementation has proven preventive effects and
is associated with lower incidence and prevalence of pneu-
monia [56, 57]. Hence, increased efforts are indicated to
improve zinc access and use in developing countries [58].
Also, considering the high prevalence of HIV infection in
sub-Saharan Africa, and that vitamin A has been shown to
reduce diarrhea in children with HIV infection or exposure,
its widespread use should be advocated as an extra tool for
containing childhood illness burden in the region [59, 60].
Probiotics might also contribute to shortened duration
and severity of diarrhea, although more evidence should be
sought before their widespread use can be recommended
[61]. Alarmingly, demographic and health survey data
collected between 1998 and 2003 and showing a decline in
use of oral rehydration therapy by as much as 32 % were
reported in Nigeria and Kenya [62, 63]. This has been
attributed to cultural beliefs and inconsistencies in health
messages from healthcare providers.
In a systematic review, Christopher et al. [64] found
promise in the practice of employing community health
workers to attain more effective delivery of cures for
malaria, pneumonia, and diarrhea in sub-Saharan Africa. In
Tanzania, it was found that first-level health care workers
were reluctant to accept IMCI guidelines, suggesting that
re-training and closer monitoring are needed [65]. It has
been shown that implementation of evidence-based treat-
ment guidelines is effective in reducing antimicrobial
resistance and hospital-acquired infections when used
appropriately [66]. A survey on use of inpatient treatment
guidelines for HIV in adults, malaria in children and adults,
pre-eclampsia, diarrhea in children, and hypertension in the
Southern Africa Development Community (SADC) identi-
fied substantial gaps in quality of evidence in available
guidelines and the extent to which they were implemented
[67]. These findings are consistent with the reality that most
health facilities in Africa have not yet adopted standard
treatment guidelines and, even where they exist, adherence
may prove to be very low. This is unfortunate, considering
that oral amoxicillin, which can be administered at home,
has been found to be as effective as parenteral penicillin in
treatment of children with uncomplicated severe commu-
nity-acquired pneumonia without hypoxia [68]. The sys-
tematic review by Christopher and colleagues concluded
that improved availability of well-trained and motivated
community health workers had the potential to reduce
childhood mortality rate from malaria, pneumonia, and
diarrhea in sub-Saharan Africa by 25–30 % [64].
While many countries in Africa now have hemophilus
influenzae type B (HIB) vaccine included in their routine
national immunization schedules, rotavirus and pneumo-
coccal vaccines have not yet gained widespread acceptance
despite their demonstrated efficacy and potential for con-
trolling childhood diarrhea and pneumonia in low-income
countries.
5.2 Impact of Antiretrovirals on Children in Botswana
in Less than a Decade
According to the 2002 UNAIDS update, more than 330,000
out of the total population of 1.5 million in Botswana had
been infected with HIV, and there were 26,000 estimated
deaths due to AIDS in 2001 alone. Statistics from 2002
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indicate that 38.8% of the economically productive and
sexually active adults (aged 15–49 years) had HIV infec-
tion/AIDS [69]. In 1997, it was estimated that AIDS
patients occupied 60 % of hospital beds in medical wards.
The large-scale effects of the AIDS epidemic in Botswana
impacted virtually all aspects of society. According to
estimations and projections by the US Bureau of the
Census, the life expectancy in Botswana in 1996 was down
from a projected 61 years in the absence of AIDS to
45 years as a result of the HIV/AIDS epidemic. Accord-
ingly, by 2010, it was estimated that the life expectancy in
Botswana would have declined further to 33 years [70].
Households faced large financial burdens due to loss of
income support from family members who died of the
disease, as well as increasing costs of treatment of HIV
infection/AIDS and associated co-morbidities [71]. Chil-
dren—being the most vulnerable in any community—were
not spared.
Before 2001, there was little access to antiretroviral
drugs (ARVs) in Botswana;\1 % of HIV-infected patients
received limited subsidy for their ARV treatment via
medical insurers [72]. Virtually no children were receiving
ARVs. Although nearly all expectant women ([95 %)
received antenatal care and delivered in hospitals or clinics
with qualified birth attendants, and free services to prevent
mother-to-child transmission of HIV (PMTCT) were
introduced in 1999, uptake remained low until routine HIV
testing ‘‘with opt-out’’ was introduced in 2004. In 2001, the
government of Botswana committed to providing highly
active antiretroviral therapy (HAART) to all qualifying
citizens. Adult patients began to access HAART in public
hospitals that year, while children followed in mid-2002.
The impact of HIV drugs and strong political will and
commitment over the last decade has been incredible.
According to the UNAIDS Botswana Country report
(2010), 90 % of all the estimated 19,000 HIV-infected
children are receiving HAART, and the proportion of
babies born to HIV-positive mothers who were infected
decreased from 20.7 % in 2003 to 3.8 % in 2007. The
mortality rate for children younger than 5 years in 1990
was 58 per 1,000 live births and worsening. Because of
non-availability of ARVs, mortality in children under 5
years of age peaked at 124 per 1000 live births in 2006 and
then dropped to 47.7 per 1000 live births by 2010—largely
due to the impact of ARVs [73].
6 Conclusions and Actions
While these brief reports show the enormous potential for
gain, there are many more examples of conditions associ-
ated with widespread morbidity and mortality where opti-
mal therapy remains an elusive goal. For example, little is
known about how best to manage the convergence of
malnutrition, hypoxia, dehydration, and sepsis in young
children. Even best practice for management of acute
malaria among infants in remote settings remains contro-
versial, although there is promise of increased survival with
the early use of rectal artesunate as an interim measure [74,
75]. Progress continues to be made in the development of
new antimalarial therapies [76, 77] and development of
effective vaccines remains a goal that many still expect to
achieve [78, 79].
Also deserving of attention by those pursuing better
drug therapies for African children is the challenge of
neglected tropical diseases. Hotez et al. [80, 81] has written
compellingly about the need to bring research capacity to
bear on conditions such as leishmaniasis, helminthic dis-
eases, trypanosomiasis, schistosomiasis, and sickle cell
anemia. While these conditions cause or contribute untold
morbidity and mortality, they tend to be ignored by usual
research sponsors, including both international agencies
and the private sector.
There are, in addition, some very practical issues in
pediatric therapeutics that are likely to gain deserved
attention from the next generation of pediatric pharma-
cologists, including, for example, burn treatment, palliative
care, management of childhood cancer, and development
of new approaches to severe pain in chronic conditions
such as cancer, sickle cell anemia, or major physical
deformities [82, 83]. A comprehensive research strategy is
urgently required.
As Voltaire observed, ‘‘best is the enemy of the good
[84].’’ The challenges to achievement of optimal therapy
for African children are numerous and daunting; however,
there are grounds for cautious optimism. Lessons can be
drawn from a number of positive initiatives, including the
WHO Make Medicines Child Size program [85], the
African Vaccine Regulatory Forum [86], the Pan African
Clinical Trials Registry [87], and the European and
Developing Countries Clinical Trials Partnership [88]. In
parallel, a compelling argument has been made by Hill and
her colleagues for adoption of a realistic focus on the
inclusion of priority medicines in evidence-based national
essential medicines lists [89]. Such developments point
toward a better future featuring science-based evolution of
African childhood therapeutics.
In conclusion, there is an immediate need for a con-
certed effort within Africa to advocate for better medicines
for children. Although many organizations have shown an
interest in this critical area, it is still important to identify a
body willing to take responsibility for continent-wide
leadership. In-country teams need to engage their Minis-
tries of Health, who can then drive the process and in turn
work with the National Drug Regulatory Authorities and
local professional and academic leaders to support
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effective structures and processes within the procurement
and supply chain systems. Key leaders from schools of
pharmacy and medicine, along with practitioners in the
fields of pharmacy, clinical pharmacology, and related
health disciplines, as well as medical and pediatric pro-
fessional associations, must all be actively engaged in this
process. Other in-country and international stakeholders
should also be enlisted to work towards better medicines
for children.
Overall, the steps that need to be taken in Africa to
improve medicinal therapy for children are known, and
there are many individuals at the country level who are
committed to working on initiatives that would help to
make essential medicines available at the right time, the
right place, and in the right formulation for children, from
infancy to adolescence. The critical element now needed is
the political will to identify the resources required to bring
these improvements to fruition across the continent.
There is a need for new north–south and south–south
partnerships that will extend current research efforts and
mobilize existing knowledge in pediatric pharmacology
and pharmacy. As part of that mobilization, it is essential to
confront the significant shortfalls in numbers of qualified
personnel able to address high priority problems or to
pursue innovative task-shifting initiatives. Educational
programs for health professionals, clinical researchers,
child health workers, pharmacologists, and pharmacists
should be urgently developed with an African perspective
and the aim of increasing the human resource base avail-
able for the research and educational efforts required.
Not all low-income countries perform to the same level
in pediatric therapeutics. Some countries have worked
consciously to develop a more child-friendly system and
have emphasized the development of appropriate treatment
guidelines while improving access to essential medicines
for children. Issues of procurement, distribution, and access
to child-appropriate drug treatment have been addressed
effectively in some, but not all, African countries. The
conclusion that some African countries do more for children
with the same or fewer resources than their peers is ines-
capable. The countries most successful in meeting the
therapeutic needs of children are those that have the polit-
ical will and have committed elected and professional
leadership to serve this cause.
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International Union of Basic and Clinical Pharmacology in Copen-
hagen. The report is not intended as a comprehensive review of
African pediatric pharmacology research but rather as an environ-
mental scan that reinforces the need for international cross-disci-
plinary effort. The opinions expressed are those of the authors and not
of the international agencies and foundations cited.
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